Davis Polk & Wardwell and Zhong Lun Law Firm advised Chinese biopharmaceutical company Antengene Corporation on its $335 million IPO in Hong Kong, with Herbert Smith Freehills and Commerce & Finance Law Offices advising the joint sponsors and the underwriters.
Antengene is a clinical-stage Asia-Pacific biopharmaceutical company offering R&D capabilities and oncology therapies.
The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which has seen a flurry of such IPOs. Recent other issuers include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.
The Herbert Smith Freehills team was led by Matt Emsley and Stanley Xie.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.